Leeds-based Surgical Innovations has reported interim results for the six months to 30 June 2025, showing revenues of £6.15m, largely unchanged from £6.18m in the same period last year. Adjusted EBITDA rose to £0.37m, up from a break-even position in H1 2024.
The company, which designs, manufactures, and distributes minimally invasive surgical technology, said its cost reduction and operational improvement initiatives from 2024 are beginning to yield results.
Sales of SI-branded products remained strong across key European markets, supported by marketing and training initiatives focused on sustainability. European growth helped offset weaker performance in the UK and US, where near-term market challenges continue. UK revenues were £2.74m, compared with £2.75m in H1 2024. US sales declined to £0.4m from £0.5m, due to the impact of tariffs and a distributor warehouse relocation.
Original equipment manufacturer (OEM) sales were below last year’s, reflecting normalisation after elevated demand in previous periods. Performance in the Rest of World segment decreased to £0.23m from £0.81m, primarily due to lost business in the Middle East and disruptions linked to conflict in the Israel region.
The company expects modest improvements in revenue and margins for the remainder of FY25, with growth momentum anticipated to continue into the first half of FY26.
